The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study

BACKGROUND: Although the positive cardiovascular effect of empagliflozin has been established, its influence on the formation of heart failure (HF) in patients with type 2 diabetes mellitus (T2D) after myocardial infarction (MI) remains unknown.

AIM: To study the effect of empagliflozin on the formation of chronic HF after MI in patients having diabetes mellitus of type 2 (DM 2), according to 12-month follow-up data.

MATERIALS AND METHODS: 47 patients with MI and DM 2 were included; 21 received standard therapy for MI and diabetes (group 1); 26 patients, in addition, received empagliflozin (group 2). The patients were investigated in 3 and 12 months, to assess the dynamics of glycemic control, 6-minute walk test, echocardiography.

RESULTS: During postinfarction period, the 6-minute walk distance was increasing in group 1 in a lesser degree (p = 0.18) than in group 2 (49.5%, p = 0.0004). The ejection fraction got better particularly in group 2 (p = 0.002). At baseline, the proportions of patients having HF with reduced and mid-range ejection fraction were 85.7% and 82.4% in groups 1 and 2 (p = 0.56) but in 12 months decreased to 71.4% and 29.4% (p = 0.012). In empagliflozin group diastolic function was improved in a third of the patients (p = 0.041). The pulmonary artery systolic pressure was increasing in group 1 (by 10,4%, p = 0.041) but decreasing in group 2 (by 24,0%, p = 0.019). Glycemic control was better in group 2 than in group 1.

CONCLUSION: According to 12-month follow-up data, empagliflozin has a positive effect on HF formation and symptoms in patients having MI and DM 2. This effect may be based on the ability of empagliflozin to improve the state of the heart including the delay of postinfarction remodeling, the improvement of pulmonary artery hemodynamics, systolic and diastolic function, the reduction of risk of chronic HF with reduced and mid-range ejection fraction.

empagliflozin, myocardial infarction, the formation of chronic heart failure

1. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. / Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. – 8-й выпуск // Сахарный диабет. — 2017. — Т. 20. — №1S. — С. 1-121. [Dedov II, Shestakova MV, Mayorov AY, et al. Dedov II, Shestakova MV, Mayorova AY, editors. Algorithms of specialized medical care for patients with diabetes mellitus. 8th ed. Diabetes mellitus. 2017;20(1S):1-121. (In Russ.)] doi: https://doi.org/10.14341/DM20171S8

2. Стронгин Л.Г., Бушуева А.В., Починка И.Г., Ботова С.Н. Сахарный диабет и госпитальная летальность при инфаркте миокарда. Данные госпитального регистра острого коронарного синдрома // Медицинский альманах. — 2018. — №4. — С. 174-177. [Strongin LG, Bushueva AV, Pochinka IG, Botova SN. Diabetes mellitus and hospital mortality in myocardial infarction. The data of the hospital registry of acute coronary syndrome. Medical Almanac. 2018;(4):174-177. (In Russ.)] doi: https://doi.org/10.21145/2499-9954-2018-4-174-177

3. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526-1534. doi: https://doi.org/10.1093/eurheartj/ehv728

4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: https://doi.org/10.1056/NEJMoa1504720

5. Balijepalli C, Shirali R, Kandaswamy P, et al. Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Ther. 2018;9(4):1491-1500. doi: https://doi.org/10.1007/s13300-018-0456-7

6. Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017;60(3):395-398. doi: https://doi.org/10.1007/s00125-016-4194-y

7. Инструкция по медицинскому применению лекарственного препарата Джардинс®. https://www.boehringer-ingelheim.ru/sites/ru/files/files/jardiance_22-10-2018.pdf [Instructions for the medical use of Jardiance® https://www.boehringer-ingelheim.ru/sites/ru/files/files/jardiance_22-10-2018.pdf]

8. Patorno E, Pawar A, Franklin J, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the empagliflozin comparative effectiveness and safety (emprise) study. In: Poceedings of the American Heart Association Scientific Sessions 2018; 2018 Nov 10-12; Chicago, IL.

9. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215-225. doi: https://doi.org/10.1007/s00125-016-4157-3

10. Kuo S, Ye W, Duong J, Herman WH. Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. Diabetes Res Clin Pract. 2018;141:181-189. doi: https://doi.org/10.1016/j.diabres.2018.04.040

11. Cai X, Ji L, Chen Y, et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. J Diabetes Investig. 2017;8(4):510-517. doi: https://doi.org/10.1111/jdi.12625

12. Scheen AJ. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract. 2016;121:204-214. doi: https://doi.org/10.1016/j.diabres.2016.09.016

13. Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458-462. doi: https://doi.org/10.1111/dom.13101

14. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J Clin Med Res. 2016;8(12):844-847. doi: https://doi.org/10.14740/jocmr2760w

15. Fioretto P, Zambon A, Rossato M, et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016;39 Suppl 2:S165-171. doi: https://doi.org/10.2337/dcS15-3006

16. Kubota Y, Yamamoto T, Tara S, et al. Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale. Diabetes Ther. 2018;9(5):2107-2116. doi: https://doi.org/10.1007/s13300-018-0480-7

17. Sattar N, McLaren J, Kristensen SL, et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333-1339. doi: https://doi.org/10.1007/s00125-016-3956-x

18. Scheen AJ. Diabetes: Time for reconciliation between cardiologists and diabetologists. Nat Rev Cardiol. 2016;13(9):509-510. doi: https://doi.org/10.1038/nrcardio.2016.113

19. Pham SV, Chilton R. EMPA-REG OUTCOME: The Cardiologist’s Point of View. Am J Med. 2017;130(6S):S57-S62. doi: https://doi.org/10.1016/j.amjmed.2017.04.006

20. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752-772. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.021887

21. Perreault L. EMPA-REG OUTCOME: The Endocrinologist’s Point of View. Am J Cardiol. 2017;120(1S):S48-S52. doi: https://doi.org/10.1016/j.amjcard.2017.05.010

22. Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39(7):1115-1122. doi: https://doi.org/10.2337/dc16-0542

23. Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479-487. doi: https://doi.org/10.1111/dom.13126

24. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017;136(17):1643-1658. doi: https://doi.org/10.1161/CIRCULATIONAHA.117.030012

25. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi: https://doi.org/10.1093/eurheartj/ehw128

26. Некрасов А.А. Иммуновоспалительные механизмы в ремоделировании сердца у больных хронической обструктивной болезнью легких. // Журнал Сердечная недостаточность. — 2011. — Т. 12. — №1. — С. 42-46. [Nekrasov AA. Immunovospalitel’nye mekhanizmy v remodelirovanii serdtsa u bol’nykh khronicheskoy obstruktivnoy bolezn’yu legkikh. Zhurnal serdechnaia nedostatochnost`. 2011;12(1):42-46. (In Russ.)]

27. Хроническая сердечная недостаточность. Клинические рекомендации Общества специалистов по сердечной недостаточности и Российского кардиологического общества. — 2016. [Khronicheskaya serdechnaya nedostatochnost’. Klinicheskie rekomendatsii Obshchestva spetsialistov po serdechnoy nedostatochnosti i Rossiyskogo kardiologicheskogo obshchestva. 2016. (In Russ.)]

28. Некрасов А.А., Тимощенко Е.С., Карпухина Е.В., Мельниченко О.В. Сердечная недостаточность с сохраненной и незначительно нарушенной фракцией выброса и сердечно-сосудистые события: патогенетические взаимосвязи как часть сердечно-сосудистого континуума // Кардиология. — 2017. — Т. 57. — №S2. — С. 337-342. [Nekrasov AA, Timoshchenko ES, Karpukhina EV, Melnichenko OV. Heart failure with preserved and slightly impaired ejection fraction and cardiovascular events: Pathogenetic interrelations as a part of the cardiovascular continuum. Cardiology. 2017;57(S2):337-342. (In Russ.)] doi: https://doi.org/10.18087/cardio.2404

29. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019;73(15):1931-1944. doi: https://doi.org/10.1016/j.jacc.2019.01.056

30. Yurista SR, Sillje HHW, Oberdorf-Maass SU, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862-873. doi: https://doi.org/10.1002/ejhf.1473